——
Real-time prices · US MarketsHealthy balance sheet and financial position.
weak profitability metrics drag quality score.
Quality
4.4
Health
5
Growth
5
Valuation
5
Sentiment
5
Analyst Target
—
Price Chart
Data not available.
Latest News
- Evolve Announces June 2026 Distributions for UltraYield ETFs and Certain Evolve Funds
- Marvell Technology Insider Sold Shares Worth $667,359, According to a Recent SEC Filing
- LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
—
next 12 months est.
Market Cap
—
market capitalization
Div Yield
—
dividend yield
Profit Margin
—
net profit margin
Gross Margin
—
revenue minus COGS
ROE
—
return on equity
Beta
—
vs S&P 500
52-Week Range
—
annual min — max
Frequently Asked Questions
What do analysts say about LGF-B right now?
LGF-B's Q·Score is 4.8/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: weak profitability metrics drag quality score. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
Is LGF-B overvalued or undervalued?
LGF-B (LGF-B) scores in line with sector averages on valuation metrics.